According to medication information through the Federal Drug Administration (FDA), Mirtazapine was developed by a company named Organon and approved by the FDA in 1996. Organon later came out with another version of the medication, Remeron SolTab, approved in 2001. In 2007, Organon was bought by Schering-Plough, which continued to market the medication. Mirtazapine is known under various other brand names in other countries; it is no longer under patent, which enables it to be distributed generically.
Mirtazapine is analogous to a medication not available in the U.S. called mianserin. Both medications act in the same way and are considered to be less dangerous in overdose than most other antidepressants.
The medication was originally intended for treating major depression, but has since been tested and investigated for a number of other uses, including:
- Generalized and social anxiety
- Obsessive-compulsive disorder
- Post-traumatic stress
- Appetite stimulation
- Sleep apnea
These off-label uses include drug addiction treatment; mirtazapine has not yet been approved by the FDA for treatment of addiction disorders.